Faron Pharmaceuticals Oy (LSE:FARN) — Stock Price
Faron Pharmaceuticals Oy (LSE:FARN) is currently trading at GBX41.00 GBX, up 0.00% today. Over the past 52 weeks, shares have ranged between GBX38.70 and GBX230.00. This page tracks Faron Pharmaceuticals Oy's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see FARN market cap overview.
Faron Pharmaceuticals Oy (FARN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Faron Pharmaceuticals Oy's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Faron Pharmaceuticals Oy Income Statement — Revenue, Profit & Earnings by Year
Faron Pharmaceuticals Oy's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | GBX0.00 | GBX0.00 | GBX0.00 | GBX0.00 | GBX0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | GBX11.74K | GBX19.54 Million | GBX20.73 Million | GBX17.37 Million | GBX13.88 Million |
| SG&A | GBX6.68 Million | GBX8.71 Million | GBX7.50 Million | GBX9.88 Million | GBX4.90 Million |
| Total Operating Expenses | GBX18.67K | GBX28.57 Million | GBX27.43 Million | GBX21.11 Million | GBX16.65 Million |
| Operating Income | GBX-18.67K | GBX-28.57 Million | GBX-27.43 Million | GBX-21.11 Million | GBX-16.65 Million |
| EBITDA | GBX-18.47K | GBX-28.37 Million | GBX-27.06 Million | GBX-20.97 Million | GBX-16.50 Million |
| EBIT | GBX-18.67K | GBX-28.57 Million | GBX-27.36 Million | GBX-21.11 Million | GBX-16.61 Million |
| Interest Expense | GBX3.85K | GBX2.17 Million | GBX1.40 Million | GBX235.00K | GBX389.00K |
| Income Before Tax | GBX-25.91K | GBX-30.94 Million | GBX-28.73 Million | GBX-21.18 Million | GBX-16.94 Million |
| Income Tax Expense | GBX5.00 | — | GBX1.30 Million | GBX16.00K | GBX10.00K |
| Net Income | GBX-25.92K | GBX-30.94 Million | GBX-28.73 Million | GBX-21.19 Million | GBX-16.95 Million |
Faron Pharmaceuticals Oy Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Faron Pharmaceuticals Oy's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | GBX12.52 Million | GBX10.22 Million | GBX11.27 Million | GBX13.18 Million | GBX8.37 Million |
| Total Current Assets | GBX11.06 Million | GBX8.87 Million | GBX9.73 Million | GBX12.02 Million | GBX7.37 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | GBX201.00K | — | GBX905.00K | GBX1.42 Million | GBX1.27 Million |
| Inventory | GBX-201.00K | — | — | — | — |
| Property, Plant & Equipment | — | — | GBX327.00K | GBX207.00K | GBX375.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | GBX22.28 Million | GBX25.38 Million | GBX22.75 Million | GBX10.26 Million | GBX10.22 Million |
| Total Current Liabilities | GBX10.17 Million | GBX15.01 Million | GBX10.47 Million | GBX7.18 Million | GBX6.50 Million |
| Long-term Debt | GBX8.09 Million | GBX9.42 Million | GBX11.10 Million | GBX2.92 Million | GBX2.73 Million |
| Net Debt | GBX2.61 Million | GBX6.24 Million | GBX6.28 Million | GBX-3.31 Million | GBX-883.00K |
| Total Stockholder Equity | GBX-9.76 Million | GBX-15.16 Million | GBX-11.48 Million | GBX2.92 Million | GBX-1.85 Million |
| Retained Earnings | GBX-197.42 Million | GBX-172.21 Million | GBX-143.71 Million | GBX-116.27 Million | GBX-96.56 Million |
Faron Pharmaceuticals Oy Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Faron Pharmaceuticals Oy generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-22.97 Million | GBX-23.81 Million | GBX-22.99 Million | GBX-22.22 Million | GBX-17.48 Million |
| Capital Expenditures | GBX226.00K | GBX123.00K | GBX385.00K | GBX474.00K | GBX142.00K |
| Free Cash Flow | GBX-23.20 Million | GBX-23.93 Million | GBX-23.38 Million | GBX-22.69 Million | GBX-17.62 Million |
| Investing Cash Flow | GBX-226.00K | GBX-123.00K | GBX-385.00K | GBX-473.00K | GBX-142.00K |
| Financing Cash Flow | GBX25.82 Million | GBX23.98 Million | GBX23.48 Million | GBX25.59 Million | GBX14.79 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | GBX694.00K | GBX2.45 Million | GBX1.30 Million | GBX1.49 Million | GBX386.00K |
| Depreciation | GBX315.00K | GBX346.00K | GBX300.00K | GBX307.00K | GBX283.00K |
| Change in Cash | GBX2.63 Million | GBX-114.00K | GBX137.00K | GBX2.75 Million | GBX-2.95 Million |
Faron Pharmaceuticals Oy Earnings History — EPS Actual vs. Analyst Estimates
Track Faron Pharmaceuticals Oy's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 04, 2026 | — | — | — |
| Aug 27, 2025 | -0.18 | -0.99 | +81.82% |
| Mar 31, 2025 | — | -0.06 | — |
| Feb 27, 2025 | -0.11 | -0.23 | +52.17% |
| Mar 02, 2023 | 0.00 | -0.18 | +100.00% |
| Aug 25, 2022 | 0.00 | -0.22 | +100.00% |
| Mar 25, 2022 | 0.00 | -0.10 | +100.00% |
| Aug 26, 2021 | 0.00 | -0.20 | +100.00% |